MDGL

MADRIGAL PHARMACEUTI

Health Care·Biotechnology·$11.8B

Reported·Q4-2017

Madrigal Pharmaceuticals Misses on EPS, Stock Down 10.89%

Metric	Actual	Expected	Surprise
EPS	$-0.67	N/A	N/A
Revenue	N/A	N/A	N/A

management commentary, guidance changes, and full analysis available with Pro.

More Earnings This Week

RYTMReported

RHYTHM PHARMACEUTICA

Mar 12, 2018

LBRTReported

LIBERTY ENERGY INC A A

Mar 12, 2018

GRBKReported

GREEN BRICK PARTNERS

Mar 12, 2018

VNETReported

VNET GROUP INC ADR

Mar 12, 2018

NTRA

Management Commentary

Tone: Defensive

Management emphasized their commitment to advancing their clinical programs. However, they did not provide any updates on future guidance.

Management did not provide specific guidance for future quarters.

The company is focusing on ongoing clinical trials and research.

What It Means

The earnings report shows that Madrigal Pharmaceuticals is still in a development phase, with no revenue reported. The stock fell significantly by 10.89%, likely due to investor disappointment over the lack of guidance and clarity on future performance. This decline reflects concerns about the company's ability to generate revenue in the near term.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime